康哲藥業(00867.HK)正常化年度溢利升23.4%至22.77億元 末期息0.1271元
格隆匯4月1日丨康哲藥業(00867.HK)公佈,截至2019年12月31日止年度,營業額增長11.8%至60.74億元人民幣(單位下同),若將“兩票制”收入還原則營業額增長12.4%至68.97億元;毛利增長16.1%至45.46億元,若將“兩票制”收入還原則毛利增長15.4%至41.73億元;正常化年度溢利增長23.4%至22.77億元;擬派末期股息每股0.1271元。
集團心腦血管線主要產品包括波依定、新活素、黛力新。於報告期內,心腦血管線實現收入26.49億元,較去年同期增長5.4%。若將“兩票制”收入還原,則心腦血管線實現收入38.04億元,較去年同期增長12.1%,佔集團還原“兩票制”營業額的55.1%。
集團消化線主要產品包括優思弗、莎爾福、億活及慷彼申。於報告期內,消化線實現收入21.86億元,較去年同期增長19.0%,佔集團還原“兩票制”營業額的31.7%。
集團眼科線主要產品為施圖倫滴眼液,於報告期內,眼科線實現收入2.58億元,較去年同期增長14.3%,佔集團還原“兩票制”營業額的3.7%。集團皮膚線主要產品為喜遼妥,於報告期內,皮膚線實現收入1.83億元,較去年同期增長15.9%,佔集團還原“兩票制”營業額的2.6%。
於報告期內,集團銷售與推廣的其他產品實現收入7.99億元,較去年同期增長14.1%。若將“兩票制”收入還原,實現收入4.68億元,較去年同期減少10.3%,佔集團還原“兩票制”營業額的6.8%。
於2019年12月31日,銀行結餘及現金為13.65億元,可隨時變現的銀行承兑匯票為4.14億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.